Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART)

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Ricardi, Umberto ^a   Racca, Patrizia ^b   Franco, Pierfrancesco ^a   Munoz, Fernando ^a   Fanchini, Laura ^b   Rondi, Nadia ^a   Dongiovanni, Vincenzo ^c   Gabriele, Pietro ^d   Cassoni, Paola ^a   Ciuffreda, Libero ^b   Morino, Mario ^e   Filippi, Andrea Riccardo ^a   Aglietta, Massimo ^d   Bertetto, Oscar ^f  

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c ASL TO5   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f NONE   (Italy)

Author keywords

Capecitabine; Oxaliplatin; Pre operative radiotherapy; Rectal cancer; Sphincter sparing surgery

Indexed keywords

CAPECITABINE; OXALIPLATIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEASIBILITY STUDY; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; MULTICENTER STUDY; NAUSEA; PEROPERATIVE COMPLICATION; PHASE 2 CLINICAL TRIAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; RECTUM CANCER; SENSORY NEUROPATHY; THROMBOCYTOPENIA; VOMITING; ABDOMINAL SURGERY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; CONSERVATIVE TREATMENT; MIDDLE AGED; PATHOLOGY; RECTUM TUMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; ORGANOPLATINUM COMPOUNDS; PROSPECTIVE STUDIES; RECTAL NEOPLASMS;

EID: 84876183898     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0581-0     Document Type: Article

References (33)

1. Valentini V, Aristei C, Glimelius B, et al. Multidisciplinary rectal cancer management: 2nd European rectal cancer consensus conference (EURECA-CC2). Radiother Oncol. 2009;92:148-63.
2. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114-23.
3. Gérard TC, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Preoperative radiotherapy with or without concurrentand leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-5.
4. Bonnetain F, Bosset JF, Gerard JP, et al. Eur J Cancer. 2012;48:1781-90.
5. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemo-radiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40.
6. Minsky BD, Roedel C, Valentini V. Combined modality therapy for rectal cancer. Cancer J. 2010;16:253-61.
7. Valvo F, Mantello G, Coco G, et al. Rectal cancer multidisciplinary treatment: evidences, consensus and perspectives. Tumori. 2010;96:185-90.
8. Rodel C, Sauer R. Integration of novel agents into combined-modality treatment for rectal cancer patients. Strahlenther Onkol. 2007;183:227-35.
9. Gerard JP, Chapet O, Nemoz C, et al. Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial. J Clin Oncol. 2003;21:1119-24.
10. Rodel C, Grabenbauer GG, Papadopoulos T, et al. PhaseI/II trial of capecitabine, oxaliplatin and radiation for rectal cancer. J Clin Oncol. 2003;21:3098-104.
11. Aschele C, Friso ML, Pucciarelli S, et al. A phase I-II study of weekly oxaliplatin, 5-forouracil continuos infusion and preoperative radiotherapy in locally advanced rectal cancer. Ann Oncol. 2005;16:1140-6.
12. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III Trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638-44.
13. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a sistematic overview of 8507 patients from 22 randomised trials. Lancet. 2001;358:1291-304.
14. Gastrointestinal Tumor Study Group. Adjuvant therapy of colon cancer: results of a prospectively randomized trial. N Engl J Med. 1984;310:737-43.
15. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-15.
16. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1995;331:502-7.
17. Ruo L, Tickoo S, Klimstra DS, et al. Long-term prognostic significance of extent of rectal response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75-81.
18. Bujko K, Nowacki MP, Nasierosska-Guttmejer A, et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol. 2004;72:15-24.
19. Van Cutsem E, Hoff PM, Harper P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer. 2004;90:1190-7.
20. Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696-704.
21. Koeberle D, Burkhard R, von Moos R, et al. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. Br J Cancer. 2008;98:1204-9.
22. Roedel C, Liersch T, Hermann RM, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25:110-7.
23. Roedel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-96.
24. Glynne-Jones R, Sebag-Montefiore D, McDonald A, et al. A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. Ann Oncol. 2006;17:50-6.
25. Machiels JP, Duck L, Honhon B, et al. Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol. 2005;16:1898-905.
26. Rutten H, Sebag-Montefiore D, Glynne-Jones R, et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: results of an international multicenter phase II study. J Clin Oncol. 2006;24(18S):(abstract 3528).
27. Glynne-Jones R, Dunst J, Sebag-Montefiore D. The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? Ann Oncol. 2006;17:361-71.
28. Aschele CP, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized trial. J Clin Oncol. 2011;29:2773-80.
29. Roh MS, Yothers GA, O' Connell MJ, et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04. Proc Am Soc Clin Oncol. 2011;29(suppl):abstract 3503.
30. Rodel C, Liersch T, Becker H, et al. Preoperative chemoradiation and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluoracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012;13:679-87.
31. Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558-65.
32. Methy N, Bedenne L, Conroy T, et al. Surrogate endpoints for overall survival and local control in neo-adjuvant rectal cancer trials: statistical evaluation based on the FFCD 9203 trial. Ann Oncol. 2010;21:518-24.
33. Tepper JE, Wang AZ. Improving local control in rectal cancer: radiation sensitizers or radiation dose? J Clin Oncol. 2010;28:1623-4.